Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSTAGE: Nintedanib + Sildenafil in IPF
NCT02802345Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of sildenafil in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Started Jun 2016; status: completed.
02
Drugs
sildenafil
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02802345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02802345.